Pfizer in Argentina
Present in Argentina since 1956, over 600 colleagues come to work every day to bring therapies to people that extend and significantly improve their lives. Our local portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. With a manufacturing plant in the City of Buenos Aires with a production capacity of 1,600 million tablets a year, we serve the local market, Latin America and other countries around the world. To learn more, please visit us at www.pfizer.com.ar
Contact:
Thames Office Park Building: Colectora Panamericana 1804, 1st floor – Sector B – South Sector
Buenos Aires, Argentina
Tel: +54 11 4788-7000
Edgardo Vázquez, Pfizer’s country manager for the Argentina Region, discusses the company’s investment strategies across their newly established business units and a few of the unique challenges presented by the…
You were General Manager of Pfizer Peru and Pfizer Venezuela before taking on the challenge of the Argentinean market. How difficult was the experience of adjusting to this unique environment?…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media…
As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover…
Pfizer’s relationship with the North African Kingdom of Morocco dates back 57 years, and the US pharma giant is the only major multinational with a manufacturing presence in the country.…
Smart manufacturing has become a key component of today’s industrial evolution and unlocked unprecedented efficiencies and quality enhancements. Smart Manufacturing expert Eric Whitley outlines the specific benefits of smart manufacturing…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more…
David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions.…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Patrick van der Loo oversees Pfizer’s operations across the vast Middle East, Russia and Africa (MERA) region. In a wide-ranging and insightful conversation, van der Loo outlines the company’s approach…
An Van Gerven took the reins of Pfizer’s BeLux affiliate just 9 months ago after a diverse range of roles at the company over the course of 12 years. She…
See our Cookie Privacy Policy Here